Application of Wharton jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis

Mahshid Saleh1*, Seyedeh Zahra Fotook Kiaei2 and Maria Kavianpour1

Abstract
Pulmonary fibrosis is a devastating disease that eventually leads to death and respiratory failure. Despite the wide range of drugs, including corticosteroids, endothelin antagonist, and pirfenidone, there is no effective treatment, and the only main goal of treatment is to alleviate the symptoms as much as possible to slow down the progression of the disease and improve the quality of life. Lung transplantation may be a treatment option for a few people if pulmonary fibrosis develops and there is no established treatment. Pulmonary fibrosis caused by the COVID19 virus is another problem that we face in most patients despite the efforts of the international medical communities. Therefore, achieving alternative treatment for patients is a great success. Today, basic research using stem cells on pulmonary fibrosis has published promising results. New stem cell-based therapies can be helpful in patients with pulmonary fibrosis. Wharton jelly-derived mesenchymal stem cells are easily isolated in large quantities and made available for clinical trials without causing ethical problems. These cells have higher flexibility and proliferation potential than other cells isolated from different sources and differentiated into various cells in laboratory environments. More clinical trials are needed to determine the safety and efficacy of these cells. This study will investigate the cellular and molecular mechanisms and possible effects of Wharton jelly-derived mesenchymal stem cells in pulmonary fibrosis.

Keywords: Stem cell, WJ-MSC, Pulmonary fibrosis, Cell-based therapy

Introduction
The lung organ is located in the chest, where the delicate lung tissue is protected by the bony and muscular cage of the chest. This tissue provides a constant flow of oxygen to the human body’s tissues, and in the meantime, the blood is cleared of carbon dioxide. Air is regularly pumped in and out through air ducts. The airways are divided into upper and lower airway systems. The transmission between the two air systems is located above the larynx [1]. Tissue fibrosis and its failure are significantly associated with mortality worldwide [2]. Fibrosis is defined by excessive deposition of connective tissue components, including myofibroblasts [3]. Fibrotic disease is usually characterized by a progressive and incomplete cycle of abnormally high accumulation of myofibroblasts [2]. It can affect almost all tissues. In this disease process, the affected organs lose their physiological function and become defective [3]. When the injury occurs, tissue microenvironmental regeneration is critical to restoring normal organ function. Inflammation and subsequent acute inflammatory reactions for various reasons, including infection or injury, can disrupt epithelial and endothelial integrity and lead to complications such as edema, leukocyte uptake, and angiogenesis. Regeneration of damaged tissue and elimination of inflammation through apoptotic and phagocytic pathways often leaves minimal damage. However, the presence of a persistent...
inflammation can cause idiopathic pulmonary fibrosis (IPF) [4, 5].

**Pulmonary fibrosis (PF)**

Pulmonary fibrosis is characterized by damage to the alveolar epithelial cells, regeneration of lung tissue, an unusual accumulation of extracellular matrix, and fibroblasts in the tissue [6, 7], which leads to respiratory failure and death [8]. When inflammation predominates, a pathogenic fibrotic reaction occurs, during which angiogenic, proinflammatory, fibrosis-causing cytokines, destructive enzymes, and growth factors accumulate at the injury site [4, 9]. The most common type of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), is a progressive disease of the lower respiratory tract with a 5-year survival rate that usually affects adults over 40 years of age [10, 11]. The factors involved in the onset of histopathological cascade in pulmonary fibrosis (PF) are unknown [12, 13]. PF-related risk factors in three categories of comorbidities, internal and external risk factors, are listed in Table 1 [14–18].

**Pathophysiology of pulmonary fibrosis**

Pulmonary fibrosis has resulted from recurrent damage to lung tissue leading to epithelial damage followed by the destruction of the alveolar-capillary basement membrane. This process causes fibroblast cells to infiltrate and myofibroblasts to become active. Eventually, the lung tissue loses its function and progresses to death [13]. Studies have shown that alveolar epithelial cell damage is an essential factor in the pathogenesis of idiopathic pulmonary fibrosis. Studies have reported type 2 alveolar cell (ATII) hyperplasia in patients with IPF [19]. In familial forms of pulmonary fibrosis, mutations in genes involved in tissue regeneration lead to damage or apoptosis of ATII cells [20]. ATII cells damage leads to ineffective reconstitution of normal epithelium and fibrosis development with activation of myofibroblasts [21, 22]. Repeated damage to the alveolar region creates a pro-inflammatory environment [2]. Inflammation leads to an abnormal wound healing response explained by genetic changes in crucial genes such as TGFb1, tumor necrosis factor-alpha (TNFα), MCP1/CCL2, MIP1a/CCL3, and surfactant protein C (SFTPC) [2, 23, 24].

TNF-α is a pleiotropic cytokine produced by a variety of cells in response to infection or damage. Improper secretion of TNF is involved in the pathogenesis of various human diseases, including infection, transplant rejection, cancer, inflammatory diseases, and pulmonary fibrosis [25, 26]. This cytokine plays an essential role in cell adhesive, inflammatory responses, migration, and activation of cytokine and chemokine cascades [27].

One of the most substantial profibrotic factors is TGF-b, which promotes lung fibrosis by using and activating monocytes and fibroblasts and producing an extracellular matrix. TGF-b1 induces fibroblast proliferation by inducing fibroblast growth factor 2 and subsequent activation of the MAPK signaling pathway [28], leading these cells to differentiate into myofibroblasts. TGF-b promotes ECM production by promoting ECM gene transcription [29]. The proinflammatory chemokines MCP1 / CCL2 and MIP1a / CCL3 are among the monocyte invoking chemokines [30]. Macrophages and fibroblasts express CCL2 / MCP-1, and its production is required for pulmonary fibrosis [31]. CCL3 / MIP-1a also helps to aggravate lung damage [32]. Studies have shown that in the BAL secretions of patients with IPF, the levels of CCL2 / MCP-1 and CCL3 / MIP-1a were increased compared to healthy individuals [33, 34].

**Wharton jelly-derived mesenchymal stem cells**

Mesenchymal stem cells are multipotent progenitor cells that can proliferate and regenerate [35]. Mesenchymal cells, like ready-made soldiers, are found in all types of adult tissues, including bone marrow, fat, skin, placenta, and heart, which migrate easily through the blood vessels when damaged by the secretion of various inflammatory factors and the invocation of inflammatory cells. Due to its surface receptors, it implants with SDF1 factors secreted from the affected area and controls the immune system by secreting various factors [36]. Rich sources of MSCs include tissues such as the placenta, umbilical cord, amniotic fluid, and amniotic membrane, considered medical waste [37]. Compared to adult tissues, stem cells isolated from the amniotic membrane (AM), chorionic plate (CP), peritoneal, and umbilical cord (UC) tissues have more advantages [38–40]. Umbilical Cord consists of two arteries and a vein inserted into a particular mucosal connective tissue known as Wharton jelly (WJ), which is covered by the amniotic epithelium. UC-MSC have a distinct capacity for self-renewal and the ability to differentiate into adipocytes, osteocytes, chondrocytes, neurons, and liver cells. In addition, when cells

---

**Table 1 Risk factors in pulmonary fibrosis**

| External risk factors          | Internal risk factors          | Co-morbidities          |
|-------------------------------|-------------------------------|-------------------------|
| Cigarette smoking             | Genetics                      | Gastroesophageal reflux |
| Environmental pollutants      | Aging                         | Obstructive sleep apnea |
| Air pollution                 | Sex                           | Diabetes mellitus       |
| Drugs                         | Lung microbiome               | Virus infection         |
| Certain occupations           |                               | Chronic aspiration      |
| Cancer treatments (radiation treatments) |                 |                         |
enter the host body, they accumulate in damaged tissue or inflamed areas and accelerate tissue repair by modulating the immune system [41, 42]. Wharton Jelly isolated from mesenchymal stem cells (hWJMSC) have been described as the best source of MSC [43]. The findings clearly show that WJ-MSC can be the best suggestion for clinical use due to its advantages such as higher proliferation and differentiation potential, easy access, easy and noninvasive separation, a large number of cells, and no ethical problems [44, 45]. Age is an essential issue in cells isolated from the donor [46]. Young donor cells in the culture medium are less exposed to damage and oxidative changes, age much more slowly and have a higher proliferation rate than the older donor [47, 48]. Because of such benefits, Wharton jelly-derived stem cells have received significant attention in various diseases. Mesenchymal stem cells secrete trophic factors that maintain cell survival, including stromal derived factor-1 (SDF-1), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF-1), epithelial growth factor (EGF), nerve growth factor (NGF), transforming growth factor-alpha (TGF-a), and tissue angiogenesis vascular endothelial growth factor (VEGF) [49]. Also, the culture medium of WJ-MSCs contains several secretory factors such as RANTES, MCP-1, MIP-1, IL-12, IL-15, IL-6, IL-8, IL-2, and PGE2. Its immunomodulatory effects mediate through these factors [50].

**Immunomodulatory effects of Wharton jelly-derived mesenchymal stem cells**

According to preclinical and clinical studies performed on hWJMSC, these cells seem to be an excellent source in cell-based reconstructive medicine and clinical trials. The WJ-MSC can also suppress the immune system and modulate the immune system through cell-to-cell contact and secretion of soluble factors, thus placing them as suitable candidates for cell therapy in allogeneic transplantation [51]. WJ-MSCs show minimal growth leukocyte antigen (HLA) class I antigen expression and no HLA-DR [52, 53]. HLA-G6 is a type of immunosuppressant produced by WJ-MSCs that inhibits the cytolytic activity of NK cells and does not express the markers CD40, CD80, or CD86 involved in T cell activation [42]. HLA- G6 is produced by trophoblasts and protects the fetus from immune-based degradation [54]. IL-6 (interleukin-6) secreted by mesenchymal stem cells isolated from the umbilical cord leads dendritic cells to tolerant phenotypes [55]. Factors such as TGF-β1, IL-10 (interleukin 10), HGF (Hepatocyte growth factor), PGE2 (prostaglandin E2), IDO (indolamine 2, 3-dioxygenase), galactin-1 are secreted by mesenchymal stem cells. They play an essential role in regulating the immune system [42, 56]. In addition, studies have shown increased expression of anti-inflammatory molecules such as CD200 or PD-L1 (programmed death ligand 1) in WJ-MSC mesenchymal stem cells [57].

MSC-derived exosomes prevent inflammatory cells from penetrating the injury site, reduce lung damage, reduce inflammatory cytokines such as TNF-α and IL-6, and multiple paracrine factors, including TNF, Angiopoietin-1, TSG-6, lipocalin-2, microRNAs, IL-37, and KGF improve survival [58–64]. Mesenchymal stem cells express the TSG-6 gene, which mediates the regulation of immune inflammation [65]. TSG-6 is another major factor that plays a vital role in the tissue repair activity of human mesenchymal stem cells, proven in models of myocardial infarction, peritonitis, and acute corneal and lung damage in mice [66, 67]. TSG-6 cleaves the binding of CXCL8 to heparin by interacting with the GAG-CXCL8 binding site to inhibit the delayed chemotactic effect of neutrophils mediated by CXCL8. In addition, TSG-6 can prevent the migration of leukocytes (mainly neutrophils and macrophages) to the site of inflammation [68]. During tissue damage and the formation of the primary inflammatory phase, proinflammatory macrophages (M1) are activated, clearing pathogenic microorganisms and forming inflammation through extracellular matrix metalloproteases (MMPs) and proinflammatory cytokines [69]. Increased anti-inflammatory M2 macrophages inhibit the inflammatory response produced by chemokines, MMPs, tissue metalloproteinase inhibitors (TIMPs), and fibronectin, leading to the progression of fibrotic lung disease [70–72]. MSCs can alter macrophage phenotypes from an inflammatory M1 phenotype to a more immunomodulatory M2 phenotype, thereby modulating macrophages [73, 74]. On the other hand, mesenchymal stem cells can increase IL-10 levels as an anti-inflammatory protein that activates regulatory cells such as Tregs [75]. Thus, mesenchymal stem cells play a significant role in immune homeostasis by interacting with cytokines, chemokines, and cell surface molecules.

**Mechanism of action of WJ-MSC on pulmonary fibrosis**

The exact mechanisms by which stem cells positively affect lung fibroids are not yet known. These mechanisms include several biological pathways, including targeted transplantation into affected areas, differentiation of stem cells into lung epithelial cells, the ability of the immune system to modulate, secretion of anti-inflammatory and anti-fibrotic factors, and the ability of the lung to repair endogenously [76]. Fibroblast activation processes through the epithelium and unfavorable response to anti-inflammatory medications are involved in developing idiopathic pulmonary fibrosis [77]. This process is associated with immune responses including...
immune cells in response to the inflammatory microenvi-
ronment. A decrease in the ratio of TGF-β1 to IL-6, indicating an increase in TGF-β1 levels with a decrease in Tregs and fibrosis-related responses in many fibrotic diseases [85, 86]. Immune cells, including macrophages, neutrophils, NK cell, T cells, and B cells, accumulate and become active at the site of inflammation and regulate the improvement and exacerbation of the fibrosis process in various fibrotic organs through various molecular mechanisms [87]. Inflammatory macrophages activate Th2 cells in lung tissue, and this inequality in the Th1 / Th2 immune response is essential in the pathogenesis of pulmonary fibrosis [88]. Macrophages also produce an effective source of fibrotic cytokines, including TGF-b1 and PDGF, chemokines, and proteases [89]. TGF-β signaling is also involved in healthy lung growth and repair of lung damage [90, 91]. This factor can induce fibroblast proliferation, differentiation, migration, and production and contraction of the extracellular matrix. In the adult lung, TGF-β-mediated overexpression of Smad3 plays a vital role in the development of extensive fibrosis [92]. In a study in patients with CTD-IP (Interstitial pneumonia in connective tissue diseases), they reported a significant increase in TGF-β1 levels with a decrease in Tregs and a decrease in the ratio of TGF-β1 to IL-6, indicating an increase in endogenous TGF-β1 which is secreted by immune cells in response to the inflammatory microenvironment. Endogenous TGF-β1 cannot differentiate Tregs due to excessive IL-6 secretion and leads to an imbalance between IL-6 and TGF-β1 in local and systemic modulation of the immune response, resulting in TGF-β1 signaling disruptions. This study examined the paradox of the TGF-β1 pro-fibrotic factor in stimulating α-SMA expression and myofibroblast differentiation and showed that excessive TGF-β1 secretion from MSC cells increased IP-10 levels in UIP-HLF (Usual interstitial pneumonia-human primary lung fibroblasts) and the simultaneous decrease in α-SMA expression (93). Thus, high levels of TGF-β1 secretion by HBMSCs may be an essential mechanism involved in the therapeutic effects of MSCs in promoting the spread of Tregs in IPF patients [94, 95].

Mesenchymal stem cells migrate to the injury site through adhesion molecules such as CXCR4, VLA-4, and CD44 [96–98] and secrete soluble factors that inhibit T cells’ maturation dendritic cells, reducing activation and proliferation. B cells and inhibition of cytotoxicity Natural killer cells regulate the adaptive and innate immune system [99–101]. Mesenchymal stem cells modulate macrophage phenotypes by diminishing profibrotic macrophage cells and inducing anti-fibrotic effects [102, 103]. WJ-MSCs prevent the uptake of neutrophils into the site of inflammation by IL-6, EGF, and TGF-α. These cells can also modulate NK cells and increase the Treg population through high levels of IGF-1 and its binding proteins [104–107]. A study in an animal model of lung damage showed that WJ-MSCs reduced inflammation and prevented the expression of TNF-α, interferon-γ, growth factor-β, MIF, and significantly reduced collagen [108]. Studies have shown the differentiation of MSCs into lung epithelial cells in a mouse model transplanted with amniotic-derived stem cells, and the CXCR4 / SDF1 axis is thought to be involved [109]. The possible mechanism of Wharton jelly-derived mesenchymal stem cells in pulmonary fibrosis is shown in Fig. 1.

Mesenchymal stem cells in animal models of pulmonary fibrosis and limitations on their use in pulmonary fibrosis Lately, adult stem cells, including mesenchymal stem cells (MSCs), have been used in preclinical and clinical trials studies due to their multilineage differentiation, safety, ability to migrate to damaged and inflamed tissue, and immunoregulatory effect in regenerative medicine and cell therapy in respiratory disease are desirable [110–112]. Numerous preclinical studies on animal models of pulmonary fibrosis have shown that mesenchymal stem cells can reduce inflammation, decrease fibrosis, and increase the survival rate [99, 113, 114]. A study by Moroncini et al. used hUC-MSC cells for intravenous injection in C57BL / 6 mice. This study showed that intravenous injection of two doses of MSC significantly decreased fibrosis and inflammation induced by bleomycin through inhibiting IL6-IL10-TGFβ factors, including a reduction in the set of lung M2 macrophages. UC-MSC also showed vigorous anti-fibrotic activity in vivo in the mouse model [115]. Another study showed that transplantation of MenSCs in a mouse model of pulmonary fibrosis significantly improves pulmonary fibrosis by assessing pathological lesions, collagen deposition, and inflammation. These cells also inhibit the apoptosis of MLE-12 cells by suppressing the expression of inflammatory cytokines [116]. A study on the IPF model showed that WJ-derived cells diminished AKT and MMP-2
Another group reported that WJ-MSC represses inflammation, diminishes myofibroblast action, and enhances MMP-9 and TLR-4 receptor expression, leading to the refusal of fibrosis [117]. Because disruption of aging-related pulmonary repair tools is likely to carry the pathogenesis of IPF, the use of younger mesenchymal stem cells may have certain benefits over other sources in the treatment of BLM-induced IPF in older patient's mice [114]. The applicability of WJ-derived MSC as an anti-fibrotic in the lung has been demonstrated in these studies.

Also, in a study by Thashiro and colleagues, they examined differences between adipose mesenchymal stem cells, young and old donors, in older mice after BLM injection. This study showed that young adipose mesenchymal stem cells reduced pro-inflammatory factors, fibrosis, MMP-2 activity, oxidative stress, and apoptotic markers, but MSC treatment of older donors in BLM mice showed associated markers and fibrosis. This model did not decrease [118]. These results suggest that these cells have age-dependent anti-fibrotic properties. It can be said that the age of donors in pulmonary fibrosis is an important issue that should be considered in cell-based clinical trials in IPF patients [76]. Therefore, the use of Wharton jelly-derived mesenchymal stem cells as a young source can provide promising results in patients with pulmonary fibrosis. In the meta-analysis article on animal models of pulmonary fibrosis, 1120 articles were included. In this study, the survival rate, the effect of MSC cells on different models of pulmonary fibrosis, type of MSC, injection route, and injection time were investigated. This study showed that MSC therapy is a safe and effective technique that can significantly ameliorate the survival and pulmonary fibrosis of animal models of pulmonary fibrosis, and this study is the basis for further clinical studies [119].

Today, animal models are used for therapeutic interventions in various diseases. However, these models face limitations. One of the most widely used models for studying pulmonary fibrosis is the BLM model. This animal model is considered an IPF characteristic due to its remarkable resemblance to human idiopathic fibrosis [120, 121]. However, the BLM model does not cover all aspects of human disease, mainly due to the progression
of fibrosis; the ability to transfer preclinical data to clinical trials is limited [76]. Although the lungs of patients with IPF are in some cases resemble the fibrotic lungs of these animals, they are not precisely equivalent to humans in the current veterinary classification of fibrotic lung disease, they are not precisely equivalent to humans in the current veterinary classification of fibrotic lung disease [122]. In addition, most therapeutic compounds have been tested on young animals, while studies have clearly shown that older mice are more prone to pulmonary fibrotic damage than younger mice [123].

Regarding efficacy, it can be said that the preclinical efficacy of most anti-fibrotic agents, which are usually tested in the BLM-induced model, is not clinically relevant based on histological examination. Also, the majority of cases in animal studies are not blind interventions for investigators [122]. Also, cases such as the non reproducibility of experiments between different laboratories and the size of selected animals to produce robust and clinically generalizable data can undermine the validity of experimental studies [122]. Therefore, designing clinical trial studies can help improve the quality of pulmonary fibrosis studies in these patients in the future.

**Clinical trial in the field of cell therapy using mesenchymal stem cells in pulmonary fibrosis**

Currently, different cells are used worldwide, including MSCs of allogeneic and autologous origin, from various adipose tissues, placenta, umbilical cord, Wharton jelly, dental pulp and menstrual, NK cell, and T cell [124]. The safety and efficacy of mesenchymal stem cells to reduce inflammatory lung disease have been shown in animal models [125]. All reports showed that stem cell injections were safe in human clinical trials. Although the effects of cell therapy are not uniform, in some studies, its positive effects have been expressed, and in other studies, these effects have not been observed [126]. The primary purpose of most of these studies is to determine the safety, feasibility, and tolerability of injected mesenchymal stem cells in patients. In a phase 1 study in patients with idiopathic pulmonary fibrosis, adipose-derived stromal cells were used. In this study, ADSCs were isolated autologously and injected intrabronchially at 0.5 × 10^6 kg body weight. The results of this study showed that no cases of severe or clinically significant long-term and short-term adverse events, including injection toxicity and abnormal tissue formation in patients, were recorded. This study also showed that intrabronchial injection of adipose-derived autologous stromal cells is safe in these patients [127]. Campo and colleagues used bone marrow-derived mesenchymal stem cells in mild to moderate pulmonary fibrosis patients. In this study, 10 × 10^6, 50 × 10^6, and 100 × 10^6 cells were injected intrabronchially into 13 patients as a single dose. The results showed that endobronchial infusion of BM-MSCs did not cause serious side effects in patients, but a related proportion of patients progressed clinically. Autologous use of MSCs for three patients appears to be troublesome due to MSC BM-BM genomic instability [128]. In another study, MSC cells in 9 patients with pulmonary fibrosis were injected intravenously with 20, 100, or 200 × 10^6 cells as a single dose. The results of this trial showed that human mesenchymal stem cell injections are safe in patients with IPF [129]. CHAMBERS et al. used placental-derived mesenchymal stem cells in 8 patients with IPF. In four patients, 1 × 10^6 and four patients, 2 × 10^6 cells were injected intravenously, and patients were monitored for six months. This study showed that intravenous injection of these cells was safe, and there was no evidence of worsening fibrosis [111]. Placenta-derived mesenchymal stem cells have received more attention today than other sources due to their ease of isolation and proliferation. In another study by Averyanov et al., 20 patients with idiopathic pulmonary fibrosis with reduced pulmonary function were selected. MSC cells were injected intravenously with 2 × 10^6 cells in two doses every three months. In these patients, no serious side effects were observed with the injection of cumulative doses of MSC. Lung function improved during the treatment period in these patients, and DLCO, FVC, and 6MWD parameters showed significant improvement [130].

In the meantime, clinical trial studies using mesenchymal stem cells in pulmonary fibrosis have been recorded at https://clinicaltrials.gov/, which is shown in Table 2.

**Possible disadvantages of using MSCs in clinical trials**

The use of new therapies such as cell therapy always has advantages and disadvantages and faces various challenges. One of the critical things in using stem cells is the tumorigenic power of these cells. The risk associated with tumorigenesis after stem cell transplantation is controversial and has been evaluated in various studies. Stem cells, like tumor cells, can proliferate for a long time, have high viability, and are resistant to apoptosis [131]. In general, donor age, recipient tissue, and growth regulators can affect transplanted mesenchymal stem cells [132, 133]. In patients undergoing long-term chemotherapy and radiotherapy, because of the immune system inadequacy, transplantation of these cells increases the risk of tumorigenesis for the patient [134]. In addition, there is a piece of evidence that the appropriate number of these cells does not reach the desired location. An insufficient number of cells reach the injury site due to their short survival and the entrapment of most of these cells after intravenous injection into the lungs [135–137]. Problems such as alloimmunization may result in the re-injection
Table 2 Clinical trials in MCS therapy on pulmonary fibrosis

| NO | Title and sponsor | Trial ID | Source of MSC | location | Design | Primary outcome | Recruitment status | Phase |
|----|-------------------|----------|----------------|----------|--------|-----------------|--------------------|-------|
| 1. | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF | NCT05016817 | UC-MSC | Island in Antigua and Barbuda | Open-Label, Interventional, Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis | Safety (adverse events) | Recruiting August 23, 2021 | Phase 1 |
| 2. | Allogeneic Human Cells (hMSC) in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) (AETHER) | NCT02013700 | – | United States, Florida | A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis | To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF) | Terminated (Study completed) March 9, 2021 | Phase 1 |
| 3. | Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement | NCT04432545 | WJ-MSC | Colombia | Expanded Access, Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton’s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment | – | Available June 16, 2020 | – |
| 4. | A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells | NCT02277145 | UC-MSC | China, Chongqing | Interventional, open-label, Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells | Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content | Completed July 24, 2019 | Phase 1 |
| 5. | Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | NCT02594839 | BM-MSC | Moscow, Russian Federation | Open-Label, Randomized, A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | Safety: Number of serious adverse events | Completed January 9, 2018 | Phase 1 |
| NO | Title and sponsor | Trial ID | Source of MSC | location | Design | Primary outcome | Recruitment status | Phase |
|----|-------------------|----------|----------------|----------|--------|----------------|--------------------|-------|
| 6. | Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis (CMM/FPI) | NCT01919827 | BM-MSC | Salamanca, Spain | Open Label, Interventional, Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells | Number of participants with adverse side effects | Completed May 3, 2018 | Phase 1 |
| 7. | Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis | NCT03187431 | BM-MSC | Egypt | Open Label, Interventional, Mesenchymal Stem Cell as Therapeutic Modality in Interstitial Pulmonary Fibrosis | Number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation | Unknown June 15, 2017 | Phase 1 |
| 8. | A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis (MSC in IPF) | NCT01385644 | PD-MSC | Minnesota, United States | Open Label, Single Group Assignment, A Phase I Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis | Number of Participants Who Demonstrated Acute Adverse Events Following Infusion | Completed December 29, 2015 | Phase 1 |
| 9. | Evaluate Safety and Efficacy of Intravenous Autologous ADMSC for Treatment of Idiopathic Pulmonary Fibrosis | NCT02135380 | AD-MSC | India | A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Safety | Unknown May 13, 2014 | Phase 1 Phase 2 |

UC-MSC Umbilical cord-derived mesenchymal stem cells, WJ-MSC Wharton's jelly-derived mesenchymal stem cells, BM-MSC bone marrow-derived mesenchymal stem cell, PD-MSC Placenta-derived mesenchymal stem cells, AD-MSC adipose tissue-derived mesenchymal stem cell
of mesenchymal stem cells, while many studies have sug-
ggested that a single MSC injection is safe for the patient
and does not stimulate the immune system [138]. In
addition, materials used to stimulate the growth and dif-
ferentiation of these cells in the laboratory environment,
including FBS, may elicit an immune response in the
patient’s body [139].

Conclusion
Wharton Jelly is a good source for extracting MSCs and
applying it in the clinic. These cells have more stemness
properties than other tissue-derived mesenchymal stem
cells, and there are no ethical problems with using these
MSCs. According to preclinical studies on mesenchymal
stem cells derived from different sources in the pulmo-
nary fibrosis model, it seems that Wharton jelly-derived
cells could be excellent sources for the treatment of this
disease in the future. Therefore, it is possible to open a
clear perspective in the treatment of pulmonary fibrosis
in the future by conducting more clinical trial studies
using WJ-MSC. In the meantime, selecting the appropri-
cate cell dose, the number of injections, injection method,
precise protocols for isolation, cell culture, and the prolif-
eration of these cells can be the beginning of a new treat-
ment procedure in patients with pulmonary fibrosis in
the future.

Abbreviations
PF: Pulmonary fibrosis; IPF: Idiopathic pulmonary fibrosis; ATII: Alveolar cell
type 2; MSCs: Mesenchymal stem cells; PD-MSCs: Placenta-derived mesen-
chymal stem cells; HBMSC: Human bone marrow-derived mesenchymal
stem cell; UC-MSC: Umbilical cord-derived mesenchymal stem cells; WJ-MSC:
Wharton’s jelly-derived mesenchymal stem cells; AD-MSC: Adipose tissue-
derived mesenchymal stem cell; HLA: Human leukocyte antigen; VEGF:
Vascular endothelial growth factor; IGF-1: Insulin-like growth factor 1; bFGF:
Basic fibroblast growth factor; NGF: Nerve growth factor; TGF-B: Transform-
ing growth beta-1; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor alpha;
SFTPC: Surfactant protein C; IL-1α: Interleukin-1 alpha; IL-10: Interleukin-10; IL-1β:
Interleukin-1 beta; SDF-1/CXCL12: Stromal cell-derived factor 1; MCP 1/CCL2:
Monocyte chemoattractant protein-1; HGF: Hepatocyte growth factor; PGE2:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
Prostaglandin E2; IDO: Indolamine 2, 3-dioxygenase; NK cell: Natural killer
cells; PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMP5:
Tissue metalloprotease inhibitors; EMT: Epithelial mesenchymal transport;
CTD-IP: Interstitial pneumonia in connective tissue diseases; UIP-HLF: Usual
Tissue metalloproteinase inhibitors; EMT: Epithelial-mesenchymal transition;
PD-L1: Programmed death ligand 1; MMPs: Matrix metalloproteases; TIMPs:
16. Ghatak S, Hascall VC, Rodriguez RM, Markwald RR, Misra S. Inflammation, wound healing, and fibrosis. Wound Healing: Stem Cells Repair and Restorations, Basic and Clinical Aspects. 2017;195.

17. Kolek V, Vašáková M, Sterclová M, Cwiertka K, Vrana D, Kudláček A, et al. Radiotherapy of lung Tumours in idiopathic pulmonary fibrosis. Klinická onkologie: casopis Ceske a Slovenske onkoligie spolecnosti. 2013;30(4):303–6.

18. Paolocci G, Folletti I, Torén K, Ekstrom M, Dell’Omo M, Muzi G, et al. Occupational risk factors for idiopathic pulmonary fibrosis in Southern Europe: a case-control study. BMC Pulm Med. 2018;18(1):1–6.

19. Katzenstein A-LA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Resp Crit Care Med. 1998;157(4):1301–15.

20. Thomas AQ, Lane K, Phillips J III, Prince M, Markin C, Speer M, et al. Heterogeneity in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3(4):364–2.

21. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Resp Crit Care Med. 2010;181(3):254–6.

22. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3(4):364–2.

23. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3(4):357–63.

24. Prasse A, Pechkovsky DV, Toews GB, Junghaenelt W, Kollett F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Resp Crit Care Med. 2006;173(7):781–92.

25. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamily: integrating mammalian biology. Cell. 2001;104(4):487–501.

26. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, et al. Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-β1 and myofibroblasts. Am J Pathol. 1998;153(3):825–32.

27. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol. 1997;158(2):954–9.

28. Khalil N, Xu YD, O’Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-β1-induced phosphorylation of p38 MAPK and JNK. J Biol Chem. 2005;280(52):43000–9.

29. Ruiz V, Ordóñez RM, Leano MJ. The TNF and TNF receptor superfamily: families. Int Rev Exp Pathol. 2007;55:697–9.

30. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH. Human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(1):63–73.

31. Wagner W, Bork S, Horn P, Kruen D, Walenda T, Diehlmann A, et al. Aging and replicative senescence have related effects on human skin progenitor cells. PLoS ONE. 2009;4(6):e5846.

32. Stollzng A, Jones E, Magonagle D, Scatt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(1):63–73.

33. Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann T, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011;20(5):655–67.

34. Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, et al. Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol. 2011;272(1):33–8.

35. Weiss ML, Anderson C, Medicetty S, Sheshadary KB, Weiss RJ, VanderWerf I, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells. 2008;26(11):2865–74.

36. Deng Y, Yi S, Wang G, Cheng J, Zhang Y, Chen W, et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 2014;23(7):2080–92.

37.Paladino FV, Sardina LR, Piccinato CA, Goldberg AC. Intrinsic variability present in Wharton’s jelly mesenchymal stem cells and T cell responses may impact cell therapy. Stem Cells Int. 2017;2017.

38. Donders R, Boige JF, Ravanidis S, Cervais P, Vanheusden M, Maree R, et al. Human Wharton's Jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev. 2018;27(2):265–84.

39. Danchar S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, et al. Human multipotent stromal cells attenuate
lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther. 2011;2(3):1–15.

59. Fang X, Neyrinck AP, Matthy MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II Cells by SECRETION OF ANGIOTENSION-1. J Biol Chem. 2010;285(34):26211–22.

60. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007;4(9):e269.

61. Krasnodaembksaya A, Song Y, Fang X, Gupta N, Senkov V, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229–38.

62. Gupta N, Krasnodaembksaya A, Kapetanaki M, Mouded M, Tan X, Senkov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67(6):533–9.

63. Monsel A, Zhu Y-G, Gennai S, Hao Q, Hu S, Rouby J-J, et al. Therapeutic effect of human mesenchymal stem cells in severe bacterial pneumonia in mice. J Immunol. 2019;203(7):1961–72.

64. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TGF-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood. 2011;118(2):330–8.

65. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as paracrine signals in severe pneumonia in mice. Am J Resp Crit Care Med. 2015;192(3):324–36.

66. Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AE, et al. Macrophage polarization in intestinal lung diseases. Central-Eur J Immunol. 2016;41(2):159.

67. Byrne AJ, Mathie SA, Gregory LG, Lloyd CM. Pulmonary macrophages: key players in the innate defence of the airways. Thorax. 2015;70(12):1189–96.

68. Gharib SA, Johnston LK, Huizari J, Birkland TP, Hanson J, Wang Y, et al. MMP2 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis. J Leukoc Biol. 2014;95(1):19–18.

69. Medbury L, James V, Ngo J, Hitos K, Wang Y, Harris D, et al. Differing association of macrophage subsets with atherosclerotic plaque stability. Int Angiol. 2013;32(1):74–8.

70. Ikonomou L, Byrne RN, van Haasten T, Vadivel A, Alphonse RS, Rey-Parra GJ, et al. Stem cell conditioned medium improves acute lung injury in mice: evidence for stem cell paracrine action. Am J Physiol-Lung Cell Mol Physiol. 2012;303(3):L967–77.

71. Asami T, Ishii M, Nakaokong H, Yagi K, Tasaka S, Asakura T, et al. Anti-inflammatory roles of mesenchymal stromal cells during acute Streptococcus pneumoniae pulmonary infection in mice. Cytotherapy. 2018;20(3):382–13.

72. Lim J-Y, Im K-S, Lee E-S, Kim N, Nam Y-S, Jeon Y-W, et al. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Sci Rep. 2016;6(1):1–13.

73. Serrano-Mollar A. Cell therapy in idiopathic pulmonary fibrosis. Med Sci. 2018;58(6):684–95.

74. Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, et al. WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119(4):772–87.

75. Koll I, Mylläriemi M, Vuorinen K, Salmikivi K, Rynänen MJ, Kinnula V-L, et al. Bone morphogenetic protein-4 inhibitor glemin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol. 2006;169(1):61–71.

76. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–51.

77. Smith JN, Witkin MD, Jogasuria AP, Christo KE, Raffay TM, Markowitz SD, et al. Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis. Sci Rep. 2020;10(1):1–10.

78. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG, et al. Diminished prostaglandin E2 contributes to the apoposis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;182(1):73–82.

79. Borok Z, Gillissen A, Buhl R, Hoyt RF, Hubbard RC, Ozaki T, et al. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Resp Dis. 1991;144(5):1080–4.

80. Jandl K, Kwapiszewska G. Stiffness of the extracellular matrix: a regulator of prostaglandins in pulmonary fibrosis? American Thoracic Society; 2020.

81. Desai O, Winkle J, Minasian M, Herzog EL. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front Immunol. 2018;9:43.
102. Luo X-Y, Meng X-J, Cao D-C, Wang W, Zhou K, Li L, et al. Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes. Stem Cell Res Ther. 2019;10(1):1–11.

103. Willis GR, Fernandez-Gonzalez A, Anatas J, Vitali SH, Liu X, Ericson M, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104–16.

104. Munir H, Luu NT, Clarke LS, Nash GB, McGettrick HM. Comparative ability of mesenchymal stromal cells from different tissues to limit neutrophil recruitment to inflamed endothelium. PLoS ONE. 2016;11(5):e0155161.

105. Anzalone R, Iacono ML, Corrao S, Magno F, Loria T, Cappello F, et al. New emerging potentials for human Wharton’s jelly mesenchymal stem cells: immunological features and hematocyte-like differentiative capacity. Stem Cells Dev. 2010;19(4):423–38.

106. Paika J, Barkowski E, Jaworski S. An accumulation of IGF-1 and IGF-binding proteins in human umbilical cord. Mol Cell Biochem. 2000;206(1):133–9.

107. Rao CV, Li X, Toth P, Lei ZM. Expression of epidermal growth factor, transforming growth factor-alpha, and their common receptor genes in human umbilical cords. J Clin Endocrinol Metab. 1995;80(3):1012–20.

108. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009;175(1):303–13.

109. Carraro G, Perin L, Sedrakyan S, Giuliani S, Tiozzo C, Lee J, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lineages. Stem Cells. 2008;26(11):2902–11.

110. Abdel Halem AS, Ahmed HH, Aglan HA, Abdel Hamid FF, Mohamed MR. Role of bone marrow-derived mesenchymal stem cells in alleviating pulmonary epithelium damage and extracellular matrix remodeling in a rat model of lung fibrosis induced by amiodarone. Biotech Histochem. 2021;96(6):418–30.

111. Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respiratory. 2014;19(7):1013–8.

112. Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, et al. Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther. 2021;12(1):410.

113. Chen J, Si L, Zhou J, Deng Y. Role of bone marrow mesenchymal stem cells in the development of PO-induced pulmonary fibrosis. Mol Med Rep. 2019;19(4):3283–90.

114. Periera-Simon S, Xia X, Catanuto P, Coronado R, Kurtzberg J, Bel-lilio M, et al. Anti-fibrotic effects of different sources of MSC in bleomycin-induced lung fibrosis in C57BL/6 male mice. Respirology. 2012;344(1):41–51.

115. Moroncini G, Paolini C, Orlando F, Capelli C, Giacca A, Tonnini C, et al. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE. 2018;13(6):e0196048.

116. Chen X, Wu Y, Wang J, Chen L, Zheng W, Zhou S, et al. Human menstrual blood-derived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and anti-inflammatory effects. Stem Cell Res Ther. 2020;11(1):1–19.

117. Chu K-A, Wang S-Y, Yeh C-C, Fu T-W, Fu Y-Y, Ko T-L, et al. Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly. Theranostics. 2016;9(22):6646–64.

118. Tashiro J, Elliott SJ, Geth DJ, Xia X, Pereira-Simon S, Choi R, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res. 2015;166(6):554–67.

119. Li D-Y, Li RF, Sun D-X, Pu D-D, Zhang Y-H. Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies. Stem Cell Res Ther. 2021;12(1):1–11.

120. Chu F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33(1):9–13.

121. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):562–82.

122. Tashiro J, Rubio GA, Limper AH, Williams K, Elliot SJ, Ninou I, et al. Exploring animal models that resemble idiopathic pulmonary fibrosis. Front Med. 2017;4:118.

123. Sueblinwong V, Neuhaj DC, Mills ST, Roser-Page S, Guidot D, Rojas M, et al. Predisposition for disrepair in the aged lung. Am J Med Sci. 2012;344(1):41–51.

124. Kaviroupan M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther. 2020;11(1):1–19.

125. Harrell CR, Sadilok R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019;2019.

126. Tsubiya A, Kojima Y, Ikashi S, Seino S, Watanabe Y, Kawata Y, et al. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflamm Regen. 2017;37(1):1–15.

127. Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Okikonomou A, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11(1):1–13.

128. Campo A, Gonzalez-Ruiz JM, Andreu E, Alcaide AB, Ocon MM, De-Torres J, et al. Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERI Open Res. 2021;7(2).

129. Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, Difede D, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial. Chest. 2017;151(5):971–81.

130. Averyanov A, Koreleva I, Konoplyannikov M, Revkova V, Lesnyak V, Kalsin V, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2020;9(1):6–16.

131. Bellagamba BC, Alireu BRD, Grivich J, Markarian CF, Camassola M, Nardi NB, et al. Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genet Mol Biol. 2016;39:129–34.

132. Hatzistergos KE, Blum A, Ince TA, Grichnik JM, Hare JM. What is the oncologic risk of stem cell treatment for heart disease? Am Heart Assoc. 2011. p. 1300–3.

133. Yubo M, Yanyan L, Li L, Tao S, Bo L, Lin C. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. PLoS ONE. 2017;12(4):e0175449.

134. Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med. 2011;9(1):1–14.

135. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15(11):1009–16.

136. Von Bahr L, Batsi I, Moll G, Hägg M, Szaksz A, Sundberg B, et al. Analysis of tissues following mesenchymal stem cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575–8.

137. Makela T, Takalo R, Arvola O, Haapenla H, Yannopoulos F, Blanco R, et al. Safety and biodistribution study of bone marrow–derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy. 2015;17(4):392–402.

138. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, et al. Immunogenicity of umbilical cord tissue-derived cells. Blood. 2008;111(1):430–8.

139. Von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Höll K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl. 2009;43(3):245–51.